SCIENION inks Joint Development and Marketing pact with AXELA
Berlin, Germany, and Toronto, Canada, MAY 24, 2016: SCIENION AG, a developer of a revolutionary new ultra-low volume liquid handling technology, is pleased to announce that it has entered into a strategic, joint development agreement with AXELA Inc.
For the full press release, click here
Johnson & Johnson Innovation Opens JLABS @ Toronto
TORONTO, May 11, 2016 Johnson & Johnson Innovation announced the opening of JLABS @ Toronto, a new 40,000-square-foot life sciences incubator, providing entrepreneurs shared lab space and offices, modular lab suites and access to scientific, industry and capital funding experts as they work to build important and successful early-stage companies.
OBIO Hosts Annual Celebration of the Health Sciences Industry in Canada
Toronto, Ontario – May 5, 2016: Ontario Bioscience Innovation Organization (OBIO®) welcomed a prestigious group of investors, companies, MPPs and industry supporters to an intimate dinner on May 3 2016 in celebration of Canada’s health science industry. The event was supported by Torys LLP and by Bloom Burton & Co.
OBIO Launches Report on Building Canada’s Health Science Industry of the Future
Toronto, Ontario – April 29, 2016: Ontario Bioscience Innovation Organization (OBIO®) today released its report “How Canada Should be Engaging in a $9 Trillion Dollar Health Economy”. The report is the output of interviews and surveys of 125 CEOs of Canada’s health science companies looking at the future of the global industry and opportunities for Ontario and Canada.
OBIO Welcomes 12 New Bioscience Companies into the OBIO CAAP Program
Toronto, Ontario - April 19, 2016: The Ontario Bioscience Innovation Organization (OBIO®) kicked off its 2016 Capital Access Advisory Program (CAAP®) on April 13, hosted at sponsor Norton Rose Fulbright, Toronto.
ImmunoBiochem Corporation partners with the CCAB at the U of T to advance new Antibody Drug Conjugates
April 18, 2016, Toronto, ON, Canada ImmunoBiochem Corporation, a Canadian biopharmaceutical company developing novel Antibody Drug Conjugates (ADCs), and the Centre for the Commercialization of Antibodies and Biologics (CCAB) have partnered to develop new therapeutics for the treatment of breast cancer and other solid tumors.
OBIO brings Innovation in Action to Queen’s Park
Toronto, Ontario – April 11, 2016: Ontario Bioscience Innovation Organization (OBIO®) hosted its annual Queen’s Park Advocacy Day on April 5, attracting an impressive 150 attendees including 50 elected officials.
OBIO CAAP Company: ChipCare on the Business News Network's "The Disruptors"
ChipCare was featured on BNN's The Disruptors this week. The focus of the interview was ChipCare's differentiation to Theranos, our Series B raise and product pipeline, and our initial focus on low and middle income countries as a smart market entry approach.
Federal Budget Misses Opportunity to Scale and Grow Health Science Companies
The 2016 Federal Liberal budget contains funding to support a much needed Innovation Agenda and promises to build globally competitive companies. At the same time the majority of this funding is directed to incubators and accelerators, granting councils and public institutions to support basic research. In order to compete in the $9 trillion global health science economy, Canada needs to devote financial resources to health science companies at the next stage of development by investing in scale up, job creation and revenue generation.
Asthma Society of Canada: Fighting for Breath: Severe Asthma Conference
Asthma Society of Canada invites you to register for the Fighting for Breath: Severe Asthma Conference
McMaster University Partners with QoC Health on SMArTVIEW Project
March 3, 2016 QoC Health is a technology partner on McMaster University’s SMArTVIEW project. The $12.3 million project has recently received a $750,000 grant from the eHealth Innovation Partnership Program (eHIPP) from Canadian Institutes of Health Research (CIHR).
Globe & Mail Report On Business Publishes Op-Ed Penned By NACO's Co-Chairs, Ian Bandeen And Bev Tudhop
March 2, 2016 Today, the Globe and Mail Report on Business published an op-ed penned by NACO's Co-Chairs, Ian Bandeen and Bev Tudhop. Titled, "For a Fraction of the Price, Angel Investors Can Pay Huge Dividends".
CAAP Company: Komodo Openlab's Tecla Launches With Bell To Provide Customers Hands-Free Access To Mobile Technology
TORONTO, Monday, February 29, 2016 — Tecla, the assistive device that provides hands-free access to technology for those with limited upper-body mobility, is about to get a whole lot more accessible for Bell customers.
OBIO Announces CONAVI Medical WINNER of OBIO First Annual Pitches and Pitchers Competition
Last night, OBIO held its first annual PITCHES AND PITCHERS COMPETITION for OBIO Pre-CAAP and CAAP companies. We are pleased to announce that Stefano Picone, Director of Finance, CONAVI Medical, received the most votes from his peers and won the competition!!
Click here for a picture of the winner!
CAAP Company: ScarX Therapeutics closes $2 million Series A financing
Feb. 16, 2016 Toronto - ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis), has closed a $2 million Series A financing. The company will complete a Phase I clinical trial of its lead candidate, SCX-001, in human volunteers, with the eventual goal of creating better functional and cosmetic patient outcomes.
OBIO applauds federal funding for Natural Products Canada
February 12, 2016 – Toronto Ontario. Today, the Ontario Bioscience Innovation Organization welcomes the creation of Natural Products Canada Inc. (NPC), the nation’s newest Centre of Excellence for Commercialization and Research. Press Release. Click here for the press release.
Self Care Cataysts - Featured Article, Inc. Magazine
Grace Soyao, Founder & CEO, Self Care Catalysts Inc. writes about "Creating Breakthroughs in Entreprneurship" in 4 key steps.
Click here for the full article
Interface Biologics Announces the Extension of its Licensing Agreement with Fresenius Medical Care
TORONTO, Canada, February 9, 2016 - Interface Biologics Inc. (IBI) is pleased to announce that Fresenius Medical Care, the worlds’ largest integrated provider of dialysis products and services, has extended their exclusive licensing agreement for use of Endexo™ technology in chronic dialysis systems to cover the acute dialysis market (including CRRT).
Focal Healthcare receives 510(k) clearance from the FDA for their targeted prostate biopsy device, Fusion Bx
Toronto, ON – January 29, 2016 – Focal Healthcare Inc.TM, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their targeted prostate biopsy device, Fusion Bx TM.
PlantForm Corporation awarded Government of Canada contract for plant-based production of anti-ricin antibody
lantForm Corporation has received a Government of Canada contract for the plant-based production of an antibody being studied by Defence Research and Development Canada (DRDC) as an antidote to ricin exposure.